-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
AX20017
Category | Virus Protease |
CAS | 329221-38-7 |
Description | AX20017 is a highly selective PknG inhibitor. It acts by blocking the proliferation of M. tuberculosis. AX20017 is shown to completely inactivate PknG-mediated blockage of lysosomal transfer and degradation of M. bovis BCG in macrophages at concentrations (10μM or higher) that does not otherwise affect the growth of BCG outside its infected host. |
Product Information
Synonyms | AX 20017; AX-20017; PknG Inhibitor; 2-(cyclopropanecarboxamido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxamide |
IUPAC Name | 2-(cyclopropanecarbonylamino)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide |
Molecular Weight | 264.35 |
Molecular Formula | C13H16N2O2S |
Canonical SMILES | C1CCC2=C(C1)C(=C(S2)NC(=O)C3CC3)C(=O)N |
InChI | InChI=1S/C13H16N2O2S/c14-11(16)10-8-3-1-2-4-9(8)18-13(10)15-12(17)7-5-6-7/h7H,1-6H2,(H2,14,16)(H,15,17) |
InChIKey | VATFNEMGBRWLHI-UHFFFAOYSA-N |
Boiling Point | 465.32°C at 760 mmHg |
Melting Point | 213.11°C |
Purity | ≥98% (HPLC) |
Density | 1.42 g/cm3 |
Solubility | Soluble in DMSO (5 mg/ml) |
Appearance | Solid powder |
Storage | 3 years-20°Cpowder 2 years-80°Cin solvent |
Complexity | 370 |
Exact Mass | 264.09324893 |
Target | Virus Protease |
XLogP3-AA | 2.2 |